NEW HAVEN, Conn., April 21, 2023 Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor,. | April 21, 2023
Arvinas, Inc. (NASDAQ:ARVN – Get Rating) has been given an average rating of “Moderate Buy” by the eighteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average twelve-month price target among […]
Psagot Value Holdings Ltd. Israel bought a new position in shares of Arvinas, Inc. (NASDAQ:ARVN – Get Rating) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 5,500 shares of the company’s stock, valued at approximately $188,000. A number of other institutional investors and hedge […]
Wells Fargo & Company downgraded shares of Arvinas (NASDAQ:ARVN – Get Rating) from an overweight rating to an equal weight rating in a research note released on Monday morning, The Fly reports. Other equities analysts have also recently issued reports about the company. Capital One Financial initiated coverage on Arvinas in a report on Tuesday, […]
Deutsche Bank AG grew its position in Arvinas, Inc. (NASDAQ:ARVN – Get Rating) by 15.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 198,903 shares of the company’s stock after buying an additional 26,469 shares during the quarter. Deutsche Bank AG’s holdings in […]
ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free.
Arvinas, Inc. (NASDAQ:ARVN – Get Rating)’s share price rose 6.8% during trading on Wednesday . The company traded as high as $38.55 and last traded at $38.45. Approximately 3,358 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 473,004 shares. The stock had previously closed at $36.01. ARVN […]
Arvinas, Inc. (NASDAQ:ARVN – Get Rating)’s share price reached a new 52-week low on Monday . The company traded as low as $37.07 and last traded at $37.07, with a volume of 3206 shares. The stock had previously closed at $40.13. A number of analysts have recently weighed in on the stock. Stifel Europe dropped […]